Global Hepatitis Therapeutics Market by Type (Hepatitis A, Hepatitis B, Hepatitis C), Drug Class (Immune Modulator, Oral Antiviral), Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Hepatitis Therapeutics Market by Type (Hepatitis A, Hepatitis B, Hepatitis C), Drug Class (Immune Modulator, Oral Antiviral), Distribution Channel - Forecast 2024-2030

Report
199 Pages
March 2024
Region: Global
360iResearch™
ID: 5715892

UP TO €848EUR$875USD£726GBP OFF until Dec 31^st 2024

The Hepatitis Therapeutics Market size was estimated at USD 29.19 billion in 2023, USD 30.76 billion in 2024, and is expected to grow at a CAGR of 4.11% to reach USD 38.71 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hepatitis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hepatitis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Bio-Rad Laboratories Inc., bioMérieux SA, Bristol-Myers Squibb Company, DiaSorin S.p.A., F. Hoffmann-La Roche AG, FUJIREBIO Inc., Gilead Sciences, Inc., Grifols S.A., Johnson & Johnson Services Inc, Merck & Co., Inc., Ortho Clinical Diagnostics, and Quest Diagnostics Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hepatitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Hepatitis A
- Hepatitis B
- Hepatitis C
Drug Class
- Immune Modulator
- Oral Antiviral
Distribution Channel
- Drug Stores
- Online
- Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Hepatitis Therapeutics Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hepatitis Therapeutics Market?
What are the technology trends and regulatory frameworks in the Hepatitis Therapeutics Market?
What is the market share of the leading vendors in the Hepatitis Therapeutics Market?
Which modes and strategic moves are suitable for entering the Hepatitis Therapeutics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Hepatitis Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of hepatitis in geriatric population
5.1.1.2. Favorable government initiatives for hepatitis treatment
5.1.1.3. Expanding healthcare infrastructure
5.1.2. Restraints
5.1.2.1. High cost of hepatitis therapeutics and diagnosis
5.1.3. Opportunities
5.1.3.1. Introduction to innovations in hepatitis elimination
5.1.3.2. Ongoing research and development activities for hepatitis therapeutics
5.1.4. Challenges
5.1.4.1. Associated side effects of hepatitis therapeutics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Hepatitis Therapeutics Market, by Type

6.1. Introduction
6.2. Hepatitis A
6.3. Hepatitis B
6.4. Hepatitis C

7. Hepatitis Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Immune Modulator
7.3. Oral Antiviral

8. Hepatitis Therapeutics Market, by Distribution Channel

8.1. Introduction
8.2. Drug Stores
8.3. Online
8.4. Pharmacies

9. Americas Hepatitis Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hepatitis Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Avantor Inc.
13.1.4. Bio-Rad Laboratories Inc.
13.1.5. bioMérieux SA
13.1.6. Bristol-Myers Squibb Company
13.1.7. DiaSorin S.p.A.
13.1.8. F. Hoffmann-La Roche AG
13.1.9. FUJIREBIO Inc.
13.1.10. Gilead Sciences, Inc.
13.1.11. Grifols S.A.
13.1.12. Johnson & Johnson Services Inc
13.1.13. Merck & Co., Inc.
13.1.14. Ortho Clinical Diagnostics
13.1.15. Quest Diagnostics Incorporated
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. HEPATITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. HEPATITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEPATITIS THERAPEUTICS MARKET DYNAMICS
FIGURE 7. HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 10. HEPATITIS THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 13. HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HEPATITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 144. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 145. HEPATITIS THERAPEUTICS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
AbbVie Inc.
Avantor Inc.
Bio-Rad Laboratories Inc.
bioMérieux SA
Bristol-Myers Squibb Company
DiaSorin S.p.A.
F. Hoffmann-La Roche AG
FUJIREBIO Inc.
Gilead Sciences, Inc.
Grifols S.A.
Johnson & Johnson Services Inc
Merck & Co., Inc.
Ortho Clinical Diagnostics
Quest Diagnostics Incorporated

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	199
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 30.76 Billion
Forecasted Market Value ( USD ) by 2030	$ 38.71 Billion
Compound Annual Growth Rate	4.1%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3270EUR$3,374USD£2,801GBP €3633EUR$3,749USD£3,112GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4142EUR$4,274USD£3,548GBP €4602EUR$4,749USD£3,942GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5014EUR$5,174USD£4,295GBP €5571EUR$5,749USD£4,772GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5887EUR$6,074USD£5,042GBP €6541EUR$6,749USD£5,602GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7631EUR$7,874USD£6,536GBP €8479EUR$8,749USD£7,262GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Hepatitis Therapeutics Market 2030 by Hepatitis Type, Drug Class, Drug Type, End-user and Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints

Hepatitis Therapeutics Global Market Report 2024

Global Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Forecast 2024-2030

Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2023-2030

Hepatitis Therapeutics - Global Strategic Business Report

About the Hepatitis Drug Market